In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nicotrol effectiveness in controlling "worst cravings" is substantiated, J&J tells NAD.

This article was originally published in The Tan Sheet

Executive Summary

NICOTROL EFFECTIVENESS IN CONTROLLING "WORST CRAVINGS" is demonstrated in the two large clinical trials submitted to FDA in support of the Rx-to-OTC switch application for the smoking cessation patch, McNeil parent Johnson & Johnson maintains in an April 15 letter to the National Advertising Division of the Council of Better Business Bureaus.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts